LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "multiple sclerosis" as a keyword



Photo by impulsq from unsplash

Assessment of Efficacy and Tolerability of Medicinal Cannabinoids in Patients With Multiple Sclerosis

Sign Up to like & get
recommendations! Published in 2018 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2018.3485

Abstract: Key Points Question Are medicinal cannabinoids effective and well tolerated in the treatment of multiple sclerosis? Findings In this systematic review and meta-analysis of 17 randomized clinical trials including 3161 patients, cannabinoids were significantly associated… read more here.

Keywords: medicinal cannabinoids; assessment efficacy; multiple sclerosis; adverse events ... See more keywords

Associations Between Findings From Myelin Water Imaging and Cognitive Performance Among Individuals With Multiple Sclerosis

Sign Up to like & get
recommendations! Published in 2020 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2020.14220

Abstract: Key Points Question Is myelin damage in normal-appearing white matter associated with cognitive impairment in participants with multiple sclerosis (MS)? Findings In this cross-sectional study of 73 participants with MS and 22 age-, sex-, and… read more here.

Keywords: cognitive performance; water imaging; multiple sclerosis; performance ... See more keywords

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy

Sign Up to like & get
recommendations! Published in 2022 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2021.44750

Abstract: Key Points Question Is early natalizumab cessation before or during the first trimester of pregnancy associated with multiple sclerosis relapse occurrence and relapse-related disability? Findings In this cohort study of 274 pregnancies, relapses during pregnancy… read more here.

Keywords: sclerosis disease; disability; natalizumab cessation; pregnancy ... See more keywords

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation

Sign Up to like & get
recommendations! Published in 2022 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2021.47588

Abstract: This cohort study investigates serum neurofilament light concentration as a biomarker associated with disability progression in multiple sclerosis in the absence of acute inflammation. read more here.

Keywords: neurofilament light; progression; acute inflammation; multiple sclerosis ... See more keywords

Factors Associated With Serological Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Rituximab

Sign Up to like & get
recommendations! Published in 2022 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2022.11497

Abstract: Key Points Question Are certain demographic or clinical factors associated with a favorable vaccine response to tozinameran among rituximab-treated patients with multiple sclerosis? Findings In this cohort study of 67 patients with multiple sclerosis, among… read more here.

Keywords: multiple sclerosis; factors associated; patients multiple; serological response ... See more keywords

Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis

Sign Up to like & get
recommendations! Published in 2022 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2022.30439

Abstract: This randomized clinical trial investigates the efficacy and safety of dimethyl fumarate vs interferon β-1a for treatment of pediatric-onset multiple sclerosis. read more here.

Keywords: onset multiple; pediatric onset; multiple sclerosis; dimethyl fumarate ... See more keywords

Considering the Future of Pediatric Multiple Sclerosis Trials After the CONNECT Open-Label Randomized Trial.

Sign Up to like & get
recommendations! Published in 2022 at "JAMA network open"

DOI: 10.1001/jamanetworkopen.2022.30451

Abstract: The approach to treatment of relapsing-remitting multiple sclerosis (RRMS) is rapidly evolving, with more than 15 disease-modifying therapies (DMTs) currently licensed for adults. Current treatment algorithms in children with multiple sclerosis (MS) remain heavily reliant… read more here.

Keywords: sclerosis; future pediatric; considering future; trial ... See more keywords

Education, Lifestyle Risk Factors, and Treatment Choices and Multiple Sclerosis Progression

Sign Up to like & get
recommendations! Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.20142

Abstract: This cohort study evaluates the association between educational level and disability progression in patients with multiple sclerosis. read more here.

Keywords: multiple sclerosis; education lifestyle; progression; risk factors ... See more keywords

Formulary Restrictions and Relapse Episodes in Persons With Relapsing-Remitting Multiple Sclerosis

Sign Up to like & get
recommendations! Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.25155

Abstract: Key Points Question Are greater Medicare Part D formulary restrictions associated with worse health outcomes for beneficiaries with relapsing-remitting multiple sclerosis (MS)? Findings In this cohort study of 84 870 Medicare beneficiaries with either stand-alone… read more here.

Keywords: multiple sclerosis; relapsing remitting; remitting multiple; relapse episodes ... See more keywords

Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability

Sign Up to like & get
recommendations! Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.31581

Abstract: This cohort study examines risk of relapse and disability progression in pregnant and nonpregnant women with moderate to severe multiple sclerosis–related disability. read more here.

Keywords: moderate severe; women moderate; multiple sclerosis; severe multiple ... See more keywords
Photo from wikipedia

Efficacy and Safety of 2 Fingolimod Doses vs Glatiramer Acetate for the Treatment of Patients With Relapsing-Remitting Multiple Sclerosis

Sign Up to like & get
recommendations! Published in 2020 at "JAMA Neurology"

DOI: 10.1001/jamaneurol.2020.2950

Abstract: Key Points Question Is treatment with a fingolimod dose of 0.5 mg or 0.25 mg superior to glatiramer acetate, 20 mg, in reducing relapse activity over 12 months in adult participants aged 18 to 65… read more here.

Keywords: relapsing remitting; treatment; fingolimod; multiple sclerosis ... See more keywords